Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Pain assessment, Psoriasis
Clinical narrative: Booster dose; body pain; Sore throat; Psoriasis gotten worse became more intense and in new areas; Pain / Burning pain; Blood work showed something was off; FACILITATED COLLECT  This is a solicited report received from contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (not available). The reporter is the patient.  A 33 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administration date 22Nov2021 (Batch/Lot number: unknown) at the age of 33 years as dose 3 (booster), single for covid-19 immunisation; adalimumab (HUMIRA), subcutaneous since 30Jul2021 (ongoing) (Batch/Lot number: unknown) at 40 mg (40 mg 1 in 14 d) for psoriatic arthropathy. Relevant medical history included: "difficulty standing from straight chair/getting in /out of bed/climbing five steps/bending to pick items from floor difficulty opening jars/opening things/needs help while walking/gripping" (unspecified if ongoing), notes: Difficulty with dressing self/cutting food/wash/dry body/taking tub bath/run errands/lifting full cup to mouth, difficulty standing from straight chair/getting in/out of bed/climbing five steps/bending to pick items from floor, difficulty opening jars/opening things/needs help while walking/gripping. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (First dose, Route of Admin: Intramuscular), for COVID-19 immunization, reaction(s): "Pain burning", "itching on left thigh/itching on right thigh", "Skin burning sensation", "Urticaria localized", "Welts", "hives/ welts/itching on right thigh, hives/ welts/ itching on left thigh"; Bnt162b2 (First dose, Route of Admin: Intramuscular), for COVID-19 immunization, reaction(s): "Butterfly rash"; Bnt162b2 (Second dose, Route of Admin: Intramuscular), for COVID-19 immunization, reaction(s): "Skin burning sensation", "Urticaria localized"; Bnt162b2 (Second dose, Route of Admin: Intramuscular), for COVID-19 immunization, reaction(s): "Butterfly rash", "itching on left thigh/itching on right thigh", "Welts", "hives/ welts/itching on right thigh, hives/ welts/ itching on left thigh". The following information was reported: PSORIASIS (medically significant) with onset 2021, outcome "unknown", described as "Psoriasis gotten worse became more intense and in new areas"; PAIN (medically significant) with onset 2021, outcome "unknown", described as "Pain / Burning pain"; BLOOD TEST ABNORMAL (medically significant) with onset 2021, outcome "unknown", described as "Blood work showed something was off"; PAIN (medically significant) with onset Nov2021, outcome "unknown", described as "body pain"; OROPHARYNGEAL PAIN (medically significant) with onset Nov2021, outcome "unknown", described as "Sore throat"; IMMUNISATION (medically significant) with onset 22Nov2021, outcome "unknown", described as "Booster dose". The patient underwent the following laboratory tests and procedures: blood test: (2021) something was off; pain assessment: (2021) 50 out of 100. The action taken for adalimumab was dosage not changed. Therapeutic measures with BENADRYL were taken as a result of psoriasis, pain, blood test abnormal, pain, oropharyngeal pain. The reporter's causality for the event(s) of , blood work showed something was off, pain/burning pain, body pain, sore throat and psoriasis gotten worse became more intense and in new areas was not provided.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: As there is limited information in the case provided, the causal association between the event PSORIASIS, PAIN, BLOOD TEST ABNORMAL, OROPHARYNGEAL PAIN, IMMUNISATION and the suspect vaccine BNT162B2 cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.